Mark Cuban has been challenging traditional drug pricing through Cost Plus Drugs since 2022, having previously criticized PBM rebates and formulary control. This response continues his strategy of contrasting the transparency of generic drug markups with the restrictions on brand-name drugs, similar to other direct sales models attempting to bypass intermediaries.

In terms of capital pathways, the company sells generic drugs at a cost-plus-15% model and attracts global demand, motivated to prove that intermediaries are the main cause of high prices. Resources flow from consumer direct purchases to a supply chain that bypasses PBMs, forming a closed loop from public pricing to policy pressure.

This is analogous to the competition between early online pharmacies and traditional chains, as well as the repeated scrutiny of PBMs in U.S. drug pricing reform. The current statement is transitioning from a commercial experiment to an industry structural critique, with the industry's position shifting from price disruptor to participant in the power struggle of the supply chain.

The structural judgment pertains to the transfer of pricing power, where PBMs lock in manufacturer channels through formulary and rebates, preventing direct sales platforms from obtaining brand-name drug supplies, resulting in the coexistence of low-priced generics and high-priced brand-name drugs, ultimately burdening consumers with intermediary markups.

ABAB News · Cognitive Law

Low-priced generics prove that intermediaries are the source of markups.
PBMs are too big to care about transparent pricing.
A 15% markup is sufficient to beat most traditional channels.